The FY23 PCARP Translational Research Partnership Award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in pancreatic cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must function as a research scientist and the other partner as a clinician investigator. It should be clear that both have had equal intellectual input in the design of the research project. Projects involving convergence science partnerships are strongly encouraged. At least one partner must have expertise either in pancreatic cancer research or pancreatic cancer patient care. Inclusion of experts from outside the pancreatic cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism. Full support for large-scale clinical trials is not expected; retrospective tissue analysis, correlative studies, or small pilot clinical trials are permitted.
Deadlines:
FY23 PCARP Focus Areas
• Early detection research for pancreatic cancer, including the prevalence in individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities • Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during diagnosis, treatment, and survivorship • Barriers to the implementation of health care, including ways to overcome socioeconomic, geographic, or ethnic and racial disparities • Identification and characterization of pancreatic cancer risk including genetic and environmental risk factors, such as diet, obesity, and microbiome • Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia • Understanding tumor development and progression, from precursors to metastasis • Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response • Biomarkers to predict therapeutic response and guide management strategies • New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance
The anticipated direct costs budgeted for the entire period of performance for an FY23 PCARP Translational Research Partnership Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
